在临床方面,Adicet Bio启动了针对晚期透明细胞肾细胞癌的CAR T细胞疗法ADI-270的I期试验。公司还开始了针对狼疮性肾炎患者的I期临床试验,并获得FDA批准将该试验扩展到包括特发性炎症性肌病和僵人综合征。

在近期的市场动态中，Adicet Bio Inc.（股票代码：ACET.US）因HC Wainwright & Co.将其评级重申为中性，引发了市场和投资者的广泛关注。这家专注于开发癌症及其他疾病疗法的临床阶段生物技术公司，正处于一个重要的转折点。了解这一评级调整的背景及其潜在影响，对投资者决策至关重要。

Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...

US-based biotechnology company Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma ...

Adicet Bio总裁兼首席执行官Chen Schor对Maltzman博士为公司增长做出贡献的能力表示信心，特别是在ADI-001和ADI-270项目的临床试验取得进展之际。Maltzman博士接替了本月结束在Adicet任期的Francesco Galimi博士。

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Adicet Bio (ACET) announced that the first patient has been dosed in the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced ccRCC. “Dosing the first patient in our Phase 1 ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Adicet Bio ( (ACET) ) has issued an update.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...